Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 5/20 | 0.43 |
| ▸ | ADH1A | P07327 | 5/20 | 0.43 |
| ▸ | ADH1C | P00326 | 4/20 | 0.43 |
| ▸ | ADH7 | P40394 | 4/20 | 0.43 |
| ▸ | ADH4 | P08319 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24607335 | 0.92 | ADH1B (0.43) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL24508685 | 0.89 | ADH1B (0.40) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL8186479 | 0.88 | ADH1B (0.54) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL22794222 | 0.87 | ADH1B (0.39) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL11569625 | 0.86 | ADH1B (0.56) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL14937478 | 0.86 | ADH1B (0.56) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL11568445 | 0.86 | ADH1B (0.56) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL11354637 | 0.86 | ADH1B (0.56) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL11153834 | 0.86 | ADH1B (0.56) | ADH1BADH1AADH1CADH7ADH4 | |
| SCHEMBL271073 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234936-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | IRAK4, IRAK2, IRAK1 | ADH1B 2976/4885ADH1A 4703/4885ADH1C 4561/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ADH1B 3094/4885ADH1A 4306/4885ADH1C 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.